Search Results

Procyrion™, Inc. announced today the completion of a $57.7 million Series E funding round, including the conversion of $10.0 million of interim financing.

Procyrion, Inc. announced the enrollment of the first patients in the company’s IDE pivotal trial.

Procyrion, Inc. announced it has successfully secured new inpatient hospital ICD-10-PCS procedure codes applicable to its Aortix™ percutaneous mechanical circulatory support technology.

Procyrion, Inc. announced today successful treatment of the first patients in the A PRIORI (Aortix therapy for Perioperative ReductIon Of Renal Injury) pilot trial to evaluate the performance of its Aortix™ percutaneous mechanical circulatory support (pMCS) device in preventing acute kidney injury (AKI) during cardiac surgery, a common and serious complication that impacts approximately 30% of patients.

Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced the schedule of presentations to be featured at the annual Transcatheter Cardiovascular Therapeutics conference in Orlando, Florida from November 4th to November 6th.

Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced successful treatment of the first patients in the company’s pilot trial to evaluate the performance of its novel Aortix™ percutaneous mechanical circulatory support device in patients with cardiorenal syndrome.

Procyrion, Inc. announced that use of its Aortix™ percutaneous mechanical circulatory support device led to rapid decongestion in a pilot study of patients admitted to the hospital with acute decompensated heart failure and worsening renal function, which is known as cardiorenal syndrome.

To date, Procyrion has raised more than $29 million in funding.